- Once-daily liraglutide, when added to insulin therapy, was associated with preservation of postprandial insulin secretion and reduction in total insulin dose in patients with newly diagnosed type 1 diabetes (T1D).
Why this matters
- Patients with newly diagnosed T1D produce little insulin.
- The mean diabetes duration was 4.4±1.2 weeks, and fasting C-peptide was 359±226 pM.
- At 52 weeks, liraglutide was associated with sustained stimulated C-peptide secretion and a greater reduction in insulin dose vs placebo (total insulin dose: 18 vs 32 IU; P<.001>
- There was no difference between the liraglutide and placebo groups in terms of stimulated C-peptide levels and total insulin dose at 58 weeks.
- The researchers observed no difference between the groups in terms of HbA1c (P=.35) or body weight (P=.87) at end of treatment.
- Adult patients with T1D who were diagnosed within 6 weeks of screening were enrolled in the 52-week trial.
- Participants were randomly assigned to once-daily liraglutide 1.8 mg (n=31) in addition to insulin therapy or placebo (n=32) plus insulin.
- Assessment of C-peptide response was conducted after a liquid mixed meal test consisting of 41 g of carbohydrate.
- Primary endpoint was area under the C-peptide curve or area under the curve (AUC) of C-peptide/AUC p-glucose after the liquid meal test.
- Funding: Novo Nordisk.
- Small sample size.